BioSpace News Archive

Regeneron Pharmaceuticals, Inc. will webcast management participation.

Poseida Therapeutics, Inc. announced that Eric Ostertag, M.D., Ph.D., has resigned as Executive Chairman and will retire from the Board of Directors effective February 3, 2023.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will make a virtual presentation at the Sequire Biotechnology Conference on Thursday, February 2 at 3:00 p.m. ET.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options.

Sarepta Therapeutics, Inc. granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on January 31, 2023.

Amgen posted the full transcript and audio replay of the company’s 2022 fourth quarter and full year financial results webcast from earlier.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that the Company has engaged New England Investors, LLC to serve as the out-licensing advisor for Envelta in the People’s Republic of China.

BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed Suresh Pisharody as its new CEO.